MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin

We analysed the prognostic significance of minimal residual disease (MRD) level in adult patients with acute myeloid leukemia (AML) treated in the randomized gemtuzumab ozogamicin (GO) ALFA-0701 trial.

Bibliographic Details
Main Authors: Lambert, Juliette, Lambert, Jérôme, Nibourel, Olivier, Pautas, Cécile, Hayette, Sandrine, Cayuela, Jean-Michel, Terré, Christine, Rousselot, Philippe, Dombret, Hervé, Chevret, Sylvie, Preudhomme, Claude, Castaigne, Sylvie, Renneville, Aline
Format: Online
Language:English
Published: Impact Journals LLC 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171629/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171629/

Similar Items